GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDS Biotechnology Corp (STU:EU6) » Definitions » EV-to-EBIT

PDS Biotechnology (STU:EU6) EV-to-EBIT : -1.99 (As of May. 23, 2024)


View and export this data going back to 2016. Start your Free Trial

What is PDS Biotechnology EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, PDS Biotechnology's Enterprise Value is €75.04 Mil. PDS Biotechnology's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-37.78 Mil. Therefore, PDS Biotechnology's EV-to-EBIT for today is -1.99.

The historical rank and industry rank for PDS Biotechnology's EV-to-EBIT or its related term are showing as below:

STU:EU6' s EV-to-EBIT Range Over the Past 10 Years
Min: -27.01   Med: 0   Max: 0
Current: -1.99

STU:EU6's EV-to-EBIT is ranked worse than
100% of 422 companies
in the Biotechnology industry
Industry Median: 10.345 vs STU:EU6: -1.99

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. PDS Biotechnology's Enterprise Value for the quarter that ended in Mar. 2024 was €88.89 Mil. PDS Biotechnology's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-37.78 Mil. PDS Biotechnology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -42.50%.


PDS Biotechnology EV-to-EBIT Historical Data

The historical data trend for PDS Biotechnology's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PDS Biotechnology EV-to-EBIT Chart

PDS Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.25 -1.30 -7.73 -8.54 -3.28

PDS Biotechnology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.60 -2.58 -2.59 -3.28 -2.51

Competitive Comparison of PDS Biotechnology's EV-to-EBIT

For the Biotechnology subindustry, PDS Biotechnology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PDS Biotechnology's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PDS Biotechnology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PDS Biotechnology's EV-to-EBIT falls into.



PDS Biotechnology EV-to-EBIT Calculation

PDS Biotechnology's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=75.037/-37.781
=-1.99

PDS Biotechnology's current Enterprise Value is €75.04 Mil.
PDS Biotechnology's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-37.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PDS Biotechnology  (STU:EU6) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

PDS Biotechnology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-37.781/88.887757
=-42.50 %

PDS Biotechnology's Enterprise Value for the quarter that ended in Mar. 2024 was €88.89 Mil.
PDS Biotechnology's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-37.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PDS Biotechnology EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of PDS Biotechnology's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


PDS Biotechnology (STU:EU6) Business Description

Traded in Other Exchanges
Address
25B Vreeland Road, Suite 300, Florham Park, NJ, USA, 07932
PDS Biotechnology Corp operates as a clinical-stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

PDS Biotechnology (STU:EU6) Headlines

No Headlines